Seer to Participate in the Morgan Stanley Global Healthcare Conference

Rhea-AI Summary

Seer, a life sciences company based in Redwood City, California, announced its participation in the Morgan Stanley Global Healthcare Conference in New York City on September 13, 2022. Management will partake in a fireside chat at 8:35 a.m. Eastern Time. The session will be available via a live webcast on the company's investor website, with an archived replay to follow. Seer specializes in proteomics, offering the Proteograph Product Suite for deep proteomic analysis, designed for research use only.

News Market Reaction – SEER

+8.72%

+8.72% Session move

In the trading session that priced this news, SEER gained 8.72%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York.

Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 13^th at 8:35 a.m. Eastern Time / 5:35 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio

 

FAQ

When is Seer's participation in the Morgan Stanley Global Healthcare Conference?

Seer will participate on September 13, 2022, at 8:35 a.m. Eastern Time.

How can I watch Seer's fireside chat at the conference?

The fireside chat will be available via a live webcast on Seer's investor website.

What is the Proteograph Product Suite developed by Seer?

The Proteograph Product Suite is an integrated solution for deep, unbiased proteomic analysis.

Is Seer's Proteograph Product intended for diagnostic use?

No, the Proteograph Product Suite is for research use only and not intended for diagnostic procedures.

Where can I find more information about Seer and its products?

More information can be found on Seer's official website at www.seer.bio.